The Board of Directors had a meeting January 28-29, and several important issues were discussed. New candidates for the IASLC Prevention and Translational fellowships were approved (see below). Plans for the 12th World Conference in Seoul, Korea, September 2-6, 2007 are moving forward. The Board of Directors focused on how to get more public and political awareness of lung cancer, and several initiatives have been taken in collaboration with the US Lung Cancer Alliance (see below). A PR committee has been established to survey options for awareness activities, and a RFP (Request for Proposal) will be released to engage a PR company for IASLC activities. Updates from several IASLC committees are presented at every Board meeting and new initiatives from the membership committee have been approved in order to increase the number of IASLC members in the different regions. A new IASLC Imaging Committee was approved with the purpose of coordinating and integrating new radiological technologies. Any member with special radiological interest is encouraged to apply to become a member of this committee. The financial situation of the organization is growing well and the Board of Directors is working with financial counselors to establish an optimal long-term financial strategy for the organization. After having met with and received proposals from several financial investment companies, the Board voted to engage with Morgan Stanley Corp. for planning future strategy.
Fred R. Hirsch
Editor, IASLC Newsletter.
IASLC/CRFA Prevention and Translational Fellowships:
The Board of Directors approved 10 new fellowships, each for $ 30,000 per year for two years. The names and mentors will be announced in the next Newsletter. The IASLC wants to thank the following sponsors for the new and previous funded two-year fellowships:
Lilly Oncology (4 fellowships), AstraZeneca (3 fellowships), GlaxoSmithKline (3 fellowships), Sanofi-Aventis (3 fellowships), Bristol-Myers Squibb (1 fellowship),
EMD Pharmaceuticals (1 fellowship) and OSI pharmaceuticals (1 fellowship).
Lung Cancer Alliance:
The US Lung Cancer Alliance is a lung cancer advocate organization that seeks to engage and educate key policymakers at the state and federal levels to promote increased funding for lung cancer. The goal is to break the vicious cycle of low survival rates and
low research dollars. The following figure shows US government funding for lung cancer
compared to other cancers.
LUNG CANCER ALLIANCE ISSUES INAUGURAL REPORT CARD ON LUNG CANCER
The Lung Cancer Alliance has recently published a US report card on lung cancer, and the IASLC community should be encouraged to make similar efforts in other regions/continents.
Nation’s Number One Cancer Killer Receives Failing Marks on Key Benchmarks
Washington, DC, Jan. 19, 2006: The Lung Cancer Alliance (LCA), the only national non-profit organization dedicated solely to advocating for people living with lung cancer or those at risk for the disease, today issued the first Report Card on Lung Cancer, an assessment of progress being made in the battle against this lethal disease. The majority of grades received were failing. Lung cancer is the number one cancer killer, resulting in 30 percent of all cancer deaths and killing more people annually than breast, prostate, colon, liver, and kidney cancers – combined. “Lung cancer is the most lethal of all major cancers,” said Laurie Fenton, President of The Lung Cancer Alliance. “This Report Card on Lung Cancer will put public health leaders and the American public on notice that it is time to change this.”
The Report Card on Lung Cancer will evaluate progress utilizing key benchmarks annually in the battle to eradicate this disease. “Lung cancer is the leading cause of cancer death in men and women,” said Paul A. Bunn, Jr., MD, and Professor of Medicine and Director of the University of the Colorado Cancer Center (UCCC); former President of the American Society of Clinical Oncology (ASCO); Member, Board of Directors, The Lung Cancer Alliance. “We have made insufficient progress in this dreaded disease in part due to a lack of resources. Hopefully, it will encourage our public health leaders to come together to develop an overall plan with a sense of urgency to increase lung cancer’s survivorship.”
The Report Card on Lung Cancer graded seven categories:
- Number of Deaths – Lung cancer is the number one cancer killer, killing three times as many men as prostate cancer, nearly twice as many women as breast cancer and more than twice as many men and women as colorectal cancer. The death rate is so high that an estimated 172,570 people were diagnosed in 2005 and approximately 163,510 died. GRADE: F
- Five-Year-Survival-Rate – Only 15% of those diagnosed live longer than five years. There has been virtually no improvement since President Nixon and Congress declared “War on Cancer” in 1971. By comparison, breast cancer’s five-year-survival rate is now 88% and prostate cancer’s is 99%. GRADE: F
- Number of Late-Stage Diagnoses – Seventy percent of diagnoses are late-stage. Late stage diagnosis is lethal diagnosis. GRADE: F
- Newly-Addicted Youth Smokers – About 2,000 new “daily” smokers under the age of 18 become addicted each day, more than 700,000 a year. GRADE: F
- Number of New Treatment and Diagnostic Options in the last 30 Years – Slight progress has been made only within the last few years. Significantly more work must be done. GRADE: D
- Federally-Supported Early Detection Program – The federal government does not support early screening for lung cancer, while it does for other major cancer with comparable public health service ratings. GRADE: F
- Overall Federal Commitment – Lacks overall plan and sense of urgency. Lung cancer is under-funded and under-researched. Only $1,829 spent per lung cancer death, compared to $23,474 per estimated breast cancer death and $14,369 per estimated prostate cancer death. GRADE: F
“It is not a surprise that The Lung Cancer Alliance would give their Newly Addicted Youth Smokers category a failing grade," said Cheryl G. Healton, Dr. P.H., President and Chief Executive Officer of the American Legacy Foundation and a Member, Board of Directors, The Lung Cancer Alliance. “Now is the time to redouble youth smoking prevention efforts.” The Report Card on Lung Cancer will be widely distributed among public policy leaders, medical professionals and health care associations working to improve outcomes for lung cancer patients.
“Because we represent patients, caregivers and those at risk for this disease, it’s clear we have much work to do,” said Ms. Fenton. “We have rolled up our sleeves and look forward to working with all those committed to improving these outcomes when the Report Card on Lung Cancer is released next year.” For more information on lung cancer, the support services of The Lung Cancer Alliance or to view the complete Report Card on Lung Cancer, visit www.lungcanceralliance.org. Statistical sources are available at www.lungcanceralliance.org.
Cancer Research and Prevention Foundation: Funding Opportunities
The Cancer Research and Prevention Foundation is a non-profit health foundation dedicated to the prevention of cancer through scientific research, education and community outreach. This year, the organization celebrates its 20 year anniversary.
The organization recently announced two year grant awards at $ 40,000 per year for a total of $ 80,000. The annual application deadlines are February 28 and September 14.
Complete information can be found at www.preventioncancer.org or by contacting Tara Partovi at e-mail firstname.lastname@example.org
Coming IASLC Workshops
February 17-19, 2006 Development of a Japanese-North American Cooperative Clinical Trial Comparing Stereotactic Radiation Therapy with Surgery for Stage I non-small cell lung cancer.
Place: Hyatt Regency, Maui, Hawaii Email: email@example.com; Contact: Dr. R. Komaki
April 26-29, 2006 2nd Latin American Conference on Lung Cancer Place: Cancun, Mexico - Email: firstname.lastname@example.org
June 18 - 21, 2006 10th Central European Lung Cancer Conference Place: Prague, Czech Republic Contact: +420-608-408-708 - Email: email@example.com For more information, visit www.conference.cz/celcc2006
June 30-July 2, 2006 Inaugural IASLC Australian Lung Cancer, Conference on Multidisciplinary Care Place: Palm Cove, North Queensland, Australia Email:firstname.lastname@example.org
September 25 - 26, 2006 11th IASLC International Workshop Early Invasive Lung Cancer: New Diagnostic Tools & Treatment Strategies. Place: Turin, Italy. Email: email@example.com For more information, visit www.congressiefiere.com
October 26-28, 2006 4th Lung & Head and Neck Conference Place: Sheraton Hotel, Chicago, Illinois. Email: firstname.lastname@example.org
November 8-12, 2006 3rd IASLC/ASCO/ESMO International Conference: "Molecular Targeted Therapies in Lung Cancer" Place: Taormina, Sicily, Italy. Email: email@example.com
November 2006 2nd Asia-Pacific Lung Cancer Conference Place: Guangzhou, China. Email: firstname.lastname@example.org Contact: Dr. Yi-Long Wu
September 2-6, 2007 The 12th World Conference on Lung Cancer - IASLC Place: Seoul, Korea Contact: Conference Secretaria. E-mail: Karen@events.com or www.iaslc.org
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
September 23 - 26 2018Toronto, Canada
November 8 - 10 2018Guangzhou, China
February 20 - 23 2019Santa Monica, California